[go: up one dir, main page]

DE60325744D1 - Zubereitung zur behandlung des nasopharyngalen carcinom und verwendung derselben - Google Patents

Zubereitung zur behandlung des nasopharyngalen carcinom und verwendung derselben

Info

Publication number
DE60325744D1
DE60325744D1 DE60325744T DE60325744T DE60325744D1 DE 60325744 D1 DE60325744 D1 DE 60325744D1 DE 60325744 T DE60325744 T DE 60325744T DE 60325744 T DE60325744 T DE 60325744T DE 60325744 D1 DE60325744 D1 DE 60325744D1
Authority
DE
Germany
Prior art keywords
treatment
nasopharyngal
carcinom
preparation
drug combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325744T
Other languages
English (en)
Inventor
Gregoire Prevost
Pierre Busson
Jean-Michel Vicat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of DE60325744D1 publication Critical patent/DE60325744D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60325744T 2002-09-27 2003-09-29 Zubereitung zur behandlung des nasopharyngalen carcinom und verwendung derselben Expired - Lifetime DE60325744D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41410302P 2002-09-27 2002-09-27
PCT/IB2003/004922 WO2004028541A2 (en) 2002-09-27 2003-09-29 Composition for the treatment of nasopharyngeal carcinoma and use thereof

Publications (1)

Publication Number Publication Date
DE60325744D1 true DE60325744D1 (de) 2009-02-26

Family

ID=32043348

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325744T Expired - Lifetime DE60325744D1 (de) 2002-09-27 2003-09-29 Zubereitung zur behandlung des nasopharyngalen carcinom und verwendung derselben

Country Status (8)

Country Link
US (2) US20060166907A1 (de)
EP (1) EP1542691B1 (de)
JP (1) JP2006500421A (de)
AT (1) ATE419852T1 (de)
AU (1) AU2003274565A1 (de)
DE (1) DE60325744D1 (de)
ES (1) ES2316811T3 (de)
WO (1) WO2004028541A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028541A2 (en) * 2002-09-27 2004-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Composition for the treatment of nasopharyngeal carcinoma and use thereof
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
EP1928237A4 (de) 2005-09-02 2011-03-09 Abbott Lab Neue heterocyclen auf imidazo-basis
US8232402B2 (en) 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
CA2743717A1 (en) 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
AR077463A1 (es) 2009-07-09 2011-08-31 Irm Llc Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias
US20180303837A1 (en) 2017-04-24 2018-10-25 Novartis Ag Therapeutic regimen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673927B2 (en) * 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
EP1140942B1 (de) * 1998-12-31 2004-03-10 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Prenyltransferase-inhibitoren
WO2001064197A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
WO2004028541A2 (en) * 2002-09-27 2004-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Composition for the treatment of nasopharyngeal carcinoma and use thereof

Also Published As

Publication number Publication date
US20080161253A1 (en) 2008-07-03
JP2006500421A (ja) 2006-01-05
ES2316811T3 (es) 2009-04-16
WO2004028541A2 (en) 2004-04-08
ATE419852T1 (de) 2009-01-15
US20060166907A1 (en) 2006-07-27
EP1542691B1 (de) 2009-01-07
AU2003274565A8 (en) 2004-04-19
EP1542691A2 (de) 2005-06-22
WO2004028541A3 (en) 2004-07-01
AU2003274565A1 (en) 2004-04-19

Similar Documents

Publication Publication Date Title
NO20034056L (no) Kombinasjoner av epotilonanaloger og kjemoterapeutiske midler for behandling av proliferative sykdommer
ATE409189T1 (de) Farnesyl transferase-hemmende 6- heterocyclylmethyl-chinolin und chinazol-derivate
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
ATE408601T1 (de) Fredericamycin-derivate
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
NO20052058D0 (no) Behandling av influensa.
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
ATE483462T1 (de) Verwendung der epothilons zur behandlung der krebs
SE0203752D0 (sv) New compounds
ATE455092T1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE60118544D1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
MX2009005795A (es) Composiciones, sintesis y metodos para usar inhibidores de colinesterasa basados en indanona.
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE323490T1 (de) Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung
DE60127537D1 (de) VERWENDUNG VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANESULFONYL-PHENYL)-PYRAZOLOÄ1,5-bÜPYRIDAZINE ZUR BEHANDLUNG VON NICHTULZERATIVER DYSPEPSIE
DE60105025D1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
HUP0301991A2 (hu) IL-18-inhibitorok alkalmazása atheroszklerózis kezelésére és/vagy megelżzésére
NO20054494L (no) Peptidvektorer
DE60325744D1 (de) Zubereitung zur behandlung des nasopharyngalen carcinom und verwendung derselben
TR200402230T4 (tr) O-ikameli 6-metil-tramadol-türevleri
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
ATE282604T1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2- abhängiger krankheiten
ATE549026T1 (de) Verwendung von pinitol zur behandlung von leberkrankheiten in säugetieren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition